Eloxx Pharmaceuticals, Inc. (ELOX) stock
ELOXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$11.74−1.01 (-7.92%)
Close on Nov 17, 2026Market cap $79.70MP/E –Yield –
Eloxx Pharmaceuticals total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Eloxx Pharmaceuticals's total debt was $0 at Jun 30, 2026. For fiscal 2025 it was $1.00M, down 84.7% from the year before. The highest annual figure on record is $14.84M in fiscal 2019.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.00M | -84.7% |
| FY2024 | Dec 31, 2024 | $6.52M | +70.1% |
| FY2023 | Dec 31, 2023 | $3.83M | -69.4% |
| FY2022 | Dec 31, 2022 | $12.54M | +4.5% |
| FY2021 | Dec 31, 2021 | $12.00M | +3.3% |
| FY2020 | Dec 31, 2020 | $11.62M | -21.7% |
| FY2019 | Dec 31, 2019 | $14.84M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $0 | -100.0% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $0 | -100.0% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $1.00M | -82.2% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $6.52M | +17.1% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $3.83M | -69.4% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $5.44M | -56.1% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $5.61M | -54.2% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $5.56M | -54.1% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $12.54M | +4.5% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $12.39M | +4.0% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $12.25M | +31.4% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $12.12M | +15.7% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $12.00M | +3.3% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $11.91M | -6.5% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $9.32M | -32.7% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $10.48M | -26.0% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $11.62M | -21.7% |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $12.74M | -13.2% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | $13.85M | -4.7% |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $14.16M | -1.6% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $14.84M | – |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | $14.68M | – |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | $14.54M | – |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | $14.39M | – |
See a number that looks wrong?